Opinion: A TB Vaccine Blueprint

With 12 new tuberculosis vaccines in clinical development, a plan is needed to introduce the most effective ones throughout the world.

Written byMichael J. Brennan and Jelle Thole
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Skin test for tuberculosisWIKIMEDIA COMMONS, CDC PUBLIC HEALTH IMAGE LIBRARY

Thousands of children, women, and men die each day from tuberculosis (TB). It is the deadliest infectious disease after HIV, and increasing drug resistance threatens to wipe out medicine’s best weapons against the TB bacterium. New tools to control the disease are needed to bring this global epidemic to a halt and prevent millions from suffering. To this end, we and others drafted “Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade,” which lays out a plan for solving the current problems caused by this ancient disease using one of the most effective and affordable public health tools modern science offers for infectious diseases: vaccines.

The only vaccine currently available for TB was developed more than 90 years ago and is ineffective against the spread ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies